Market Cap 2.69B
Revenue (ttm) 0.00
Net Income (ttm) -413.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 957,700
Avg Vol 1,302,372
Day's Range N/A - N/A
Shares Out 170.92M
Stochastic %K 95%
Beta 0.61
Analysts Strong Sell
Price Target $43.38

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relatin...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 580 3099
Address:
320 West 37th Street, 6th Floor, New York, United States
zeustony88
zeustony88 Jun. 26 at 9:46 PM
$IMVT Added to watch list
0 · Reply
History101
History101 Jun. 25 at 8:53 PM
$IMVT I assume $ROIV still owns ~ 64% of IMVT, if anyone knows any different plz let us know, thanks
0 · Reply
History101
History101 Jun. 25 at 8:48 PM
$IMVT short interest, per Barron's, 5/30/2025: 21.7MM shares short (up 1.3% from 5/15/2025) 31.6% of float 13.7 days to cover
0 · Reply
toro365
toro365 Jun. 23 at 2:15 PM
$IMVT Sold here. Don't trust this market Good luck bulls
0 · Reply
toro365
toro365 Jun. 20 at 4:39 PM
$IMVT Inverted H&S
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 20 at 3:30 PM
$IMVT squeeze candidate above that base
0 · Reply
toro365
toro365 Jun. 20 at 3:28 PM
$IMVT Buying at this level
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 19 at 4:50 PM
$IMVT caught a nice bid on Friday. One to watch for a squeeze move.
2 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 17 at 3:02 PM
$IMVT hourly chart of this low-float, heavy-short biotech stocks is reversing from the pink zone of the uptrending LRC. Good squeeze potential here on breakout over today's high.
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 16 at 7:37 PM
$IMVT: bombed out last week for us...but not a bad look here. I still have a few on board.
0 · Reply
Latest News on IMVT
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 27, 2024, 10:50 AM EST - 6 months ago

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study


Top 2 Health Care Stocks That May Collapse This Quarter

Sep 9, 2024, 9:12 AM EDT - 10 months ago

Top 2 Health Care Stocks That May Collapse This Quarter

TERN


Immunovant Awarded U.S. Patent for IMVT-1402

Mar 12, 2024, 7:30 AM EDT - 1 year ago

Immunovant Awarded U.S. Patent for IMVT-1402


Immunovant to Present at Upcoming Investor Conferences

Nov 13, 2023, 8:00 AM EST - 1 year ago

Immunovant to Present at Upcoming Investor Conferences


Immunovant Could Be Poised For A Breakout In H2 2023

May 24, 2023, 1:14 PM EDT - 2 years ago

Immunovant Could Be Poised For A Breakout In H2 2023


Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Sep 28, 2022, 10:45 AM EDT - 2 years ago

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn


zeustony88
zeustony88 Jun. 26 at 9:46 PM
$IMVT Added to watch list
0 · Reply
History101
History101 Jun. 25 at 8:53 PM
$IMVT I assume $ROIV still owns ~ 64% of IMVT, if anyone knows any different plz let us know, thanks
0 · Reply
History101
History101 Jun. 25 at 8:48 PM
$IMVT short interest, per Barron's, 5/30/2025: 21.7MM shares short (up 1.3% from 5/15/2025) 31.6% of float 13.7 days to cover
0 · Reply
toro365
toro365 Jun. 23 at 2:15 PM
$IMVT Sold here. Don't trust this market Good luck bulls
0 · Reply
toro365
toro365 Jun. 20 at 4:39 PM
$IMVT Inverted H&S
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 20 at 3:30 PM
$IMVT squeeze candidate above that base
0 · Reply
toro365
toro365 Jun. 20 at 3:28 PM
$IMVT Buying at this level
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 19 at 4:50 PM
$IMVT caught a nice bid on Friday. One to watch for a squeeze move.
2 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 17 at 3:02 PM
$IMVT hourly chart of this low-float, heavy-short biotech stocks is reversing from the pink zone of the uptrending LRC. Good squeeze potential here on breakout over today's high.
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 16 at 7:37 PM
$IMVT: bombed out last week for us...but not a bad look here. I still have a few on board.
0 · Reply
swingingtech
swingingtech Jun. 5 at 11:12 AM
$SCHK $IMVT $ZETA $RVMD https://wallstreetwaves.com/how-the-pieces-add-up-schk-headed-for-32/
0 · Reply
YasirTrades
YasirTrades Jun. 4 at 7:20 AM
Guys I found the next monster runner like The ones below! Look into GLMD, Monster catalysts any day. Former runner to $24 $RCUS$2 to $25+ on immuno-oncology buzz $MBOT — from $3 to $18 in one day off a surgical device catalyst $IMVT — low float + GLP-1 buzz = 10x in under a year
2 · Reply
ZacksResearch
ZacksResearch May. 30 at 1:54 PM
$IMVT gains 5.6% following better-than-expected earnings results Immunovant’s Q4 loss of 64 cents per share was narrower than the Zacks Consensus Estimate of 72 cents. The company, which currently has no approved products, is pinning its hopes on IMVT-1402, with clinical studies planned across 10 indications by March 2026. Discover the full story here 👉 https://www.zacks.com/commentary/2479368/imvt-q4-loss-narrower-than-expected-stock-up-pipeline-in-focus?cid=sm-stocktwits-2-2479368-body&ADID=SYND_STOCKTWITS_TWEET_2_2479368_BODY
0 · Reply
ZacksResearch
ZacksResearch May. 30 at 12:11 PM
$IMVT stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications. Read further: https://www.zacks.com/stock/news/2479368/imvt-q4-loss-narrower-than-expected-stock-up-pipeline-in-focus?cid=sm-stocktwits-2-2479368-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2479368_TEASER
0 · Reply
kadeee
kadeee May. 29 at 7:36 PM
$TRIB Hello earnings! $IMVT $IMNN
1 · Reply
Romaleos
Romaleos May. 29 at 5:19 PM
$IMVT I'm in. +$34.2 soon
0 · Reply
mikesterz7
mikesterz7 May. 29 at 3:52 PM
$IMVT Its candidate IMVT-1402 is being developed for the treatment of multiple illnesses, including Graves’ disease (GD), difficult-to-treat Rheumatoid Arthritis (D2T RA), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Sjögren’s Disease (SjD).
0 · Reply
d_risk
d_risk May. 29 at 3:11 PM
$IMVT - Immunovant Inc. Common Stock - 10K - Updated Risk Factors IMVT’s 2025 10-K reveals heightened risks around regulatory approval delays, extensive costly clinical trials, commercialization challenges, intensified IP litigation and licensing uncertainties, reliance on HanAll agreements, evolving healthcare laws, cybersecurity threats, market acceptance hurdles, limited commercialization experience, and new governance and stock volatility risks. #Biotechnology #HealthcareLaws #IntellectualProperty #ClinicalTrials #RegulatoryRisks 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-K/2025-05-29
0 · Reply
StocktwitsNews
StocktwitsNews May. 29 at 2:41 PM
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence $ $IMVT $VTI $XBI https://stocktwits.com/news/equity/markets/immunovant-reports-narrower-than-expected-q1-loss/ch0AAz4Rbts
0 · Reply
DonCorleone77
DonCorleone77 May. 29 at 11:14 AM
$IMVT Immunovant sees cash runway through GD readout expected in 2027 As of March 31, 2025, Immunovant's cash and cash equivalents totaled approximately $714 million, providing runway for announced indications through GD readout expected in 2027.
0 · Reply
DonCorleone77
DonCorleone77 May. 29 at 11:10 AM
$IMVT Immunovant sees cash runway through GD readout expected in 2027 As of March 31, 2025, Immunovant's cash and cash equivalents totaled approximately $714 million, providing runway for announced indications through GD readout expected in 2027.
0 · Reply
DonCorleone77
DonCorleone77 May. 29 at 11:10 AM
$IMVT Immunovant reports Q4 EPS (64c), consensus (72c) In April 2025, Immunovant announced changes to its leadership team as part of a broader strategic transition with Roivant increasing operational involvement and oversight of Immunovant. Eric Venker, M.D. was appointed as CEO of Immunovant, and Tiago Girao as CFO of Immunovant. Given the strength of its potential best-in-class profile, IMVT-1402 is being developed in six announced indications, including potentially registrational trials in Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjogren's disease, and a proof-of-concept trial in cutaneous lupus erythematosus. In March 2025, Immunovant announced positive results from its batoclimab MG and CIDP studies. The potentially registrational study in MG met its primary endpoint of change from baseline in Myasthenia Gravis Activities of Daily Living score in the AChR+ population at week 12, with the higher dose arm achieving a 5.6-point improvement and the lower dose arm achieving a 4.7-point improvement. Initial results from week 12 of the Phase 2b CIDP study demonstrated a mean improvement in the adjusted Inflammatory Neuropathy Cause and Treatment disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%. In both batoclimab studies, deeper IgG reductions correlated with improved clinical outcomes across a range of assessments and timepoints. Potentially registrational trials for IMVT-1402 in both MG and CIDP are actively enrolling. In March 2025, Immunovant initiated a potentially registrational trial of IMVT-1402 in adult participants with active, anti-citrullinated protein autoantibody positive D2T RA and a proof-of-concept study in CLE. Both indications represent potential first-in-class and best-in-class opportunities based on positive in-class competitor data and promising efficacy data from patients dosed with IMVT-1402 as part of an open-label case study program. Immunovant plans to initiate a potentially registrational trial evaluating IMVT-1402 in SjD and a second potentially registrational trial in GD in the summer of 2025. Immunovant expects to report batoclimab six-month remission data from the proof-of-concept study in GD in the summer of 2025 and Phase 3 thyroid eye disease data in the second half of calendar year 2025.
0 · Reply